Medicare Benefits Schedule - Item 73333

Detection of germline mutations of the von Hippel-Lindau (VHL) gene:

(a)    in a patient who has a clinical diagnosis of VHL syndrome and:

(i)    a family history of VHL syndrome and one of the following:

(A)     haemangioblastoma (retinal or central nervous system);

(B)     phaeochromocytoma;

(C)     renal cell carcinoma; or

(i)    2 or more haemangioblastomas; or

(ii)    one haemangioblastoma and a tumour or a cyst of:

(A)     the adrenal gland; or

(B)     the kidney; or

(C)    the pancreas; or

(D)     the epididymis; or

(E)     a broad ligament (other than epididymal and single renal cysts, which are common in the general population); or

(a)    in a patient presenting with one or more of the following clinical features suggestive of VHL syndrome:

    (i)    haemangioblastomas of the brain, spinal cord, or retina;

    (ii)    phaeochromocytoma;

    (iii)    functional extra-adrenal paraganglioma

Fee: $600.00 Benefit: 75% = $450.00 85% = $512.10

(See para PN.0.27 of explanatory notes to this Category)

• Previous - Item 73332
• Next - Item 73334

Patients who are found to have any form of affected allele should be referred for post-test genetic counselling as there may be implications for other family members. Appropriate genetic counselling should be provided to the patient either by the specialist treating practitioner, a genetic counselling service or a clinical geneticist on referral.

Related Items: 73295 73296 73304 73333